NoNO-42 / NoNO - LARVOL DELTA

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy (clinicaltrials.gov) - P2 | N=600 | Recruiting | Sponsor: NoNO Inc. | Trial completion date: May 2026 ➔ Dec 2026 | Trial primary completion date: May 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

ACT-GLOBAL Adaptive Platform Trial for Stroke (clinicaltrials.gov) - P3 | N=20000 | Recruiting | Sponsor: The George Institute | Not yet recruiting ➔ Recruiting | Trial completion date: May 2034 ➔ Sep 2034 | Initiation date: May 2024 ➔ Sep 2024 | Trial primary completion date: May 2034 ➔ Sep 2034

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis with or Without Endovascular Thrombectomy (clinicaltrials.gov) - P2 | N=600 | Recruiting | Sponsor: NoNO Inc. | Not yet recruiting ➔ Recruiting | Initiation date: May 2024 ➔ Oct 2024

Enrollment open • Trial initiation date • Cardiovascular • Ischemic stroke

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults (clinicaltrials.gov) - P1 | N=83 | Completed | Sponsor: NoNO Inc. | Recruiting ➔ Completed | N=44 ➔ 83

Enrollment change • Trial completion • Cardiovascular • Ischemic stroke

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy (clinicaltrials.gov) - P2 | N=600 | Not yet recruiting | Sponsor: NoNO Inc.

New P2 trial • Cardiovascular • Ischemic stroke

ACT-GLOBAL Adaptive Platform Trial for Stroke (clinicaltrials.gov) - P3 | N=20000 | Not yet recruiting | Sponsor: The George Institute | Trial primary completion date: Apr 2024 ➔ May 2034

Trial primary completion date • Cardiovascular

ACT-GLOBAL Platform Trial for Stroke (clinicaltrials.gov) - P3 | N=20000 | Not yet recruiting | Sponsor: The George Institute

New P3 trial • Cardiovascular

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: NoNO Inc. | Trial completion date: May 2023 ➔ Oct 2023 | Trial primary completion date: May 2023 ➔ Oct 2023

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: NoNO Inc.

New P1 trial • Cardiovascular • Ischemic stroke